Schrodinger, Inc. (SDGR) Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Software - Application
Schrodinger, Inc. Common Stock NASDAQ:SDGR Technology · Software - Application
Mkt Cap $1.94B
EV -
SI 18.6%
Net Cash/Sh -
Prev close $27.36 +0.58%Open $27.52 -6.05%Now $25.86 VOL 846K $ Vol $22.11M RVOL 0.52x
Mkt Cap $1.94B
EV -
VOL 846K sh
$ Vol $22.11M
RVOL 0.52×
SI 18.6%
Net Cash/Sh -
Press Release ● Major
Schrödinger Reports Third Quarter 2026 Financial Results
businesswire.com • 12d ago Press Release
Schrödinger to Present at UBS Global Healthcare Conference
businesswire.com • 20d ago Press Release ● Major
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • 22d ago Press Release
Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry
businesswire.com • 1mo ago Press Release ● Major
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • 2mo ago Press Release
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
businesswire.com • 2mo ago Press Release
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
businesswire.com • 2mo ago Press Release ● Major
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • 3mo ago Press Release ● Major
Schrödinger Reports Second Quarter 2026 Financial Results
businesswire.com • 3mo ago Press Release
Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
businesswire.com • 3mo ago Press Release
Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery
businesswire.com • 3mo ago Press Release ● Major
Schrödinger to Announce Second Quarter 2026 Financial Results on August 5
businesswire.com • 3mo ago Press Release ● Major
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • 3mo ago Press Release ● Major
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • 4mo ago Press Release
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
Equity Insider published a paid commentary on behalf of MindWalk Holdings Corp., arguing that the value in AI drug discovery lies in the underlying biological data layer rather than just the models. The article profiles MindWalk's 'context layer' strategy and mentions Absci (ABSI) as a peer focused on generative design and a participant in a recent industry panel.
• 5mo ago AI analysis › Press Release
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • 7mo ago